Impact of the COVID-19 pandemic on childhood asthma
Consequences of SARS-CoV2 Pandemic on Childhood Asthma Control and Exacerbations: French Multicenter Cross-sectional VIRASTHMA COVID G4 Study
This study looks at how the COVID-19 pandemic has changed asthma control in children aged 3-16 by comparing their current symptoms to those before the pandemic.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 577 (estimated) |
| Ages | 3 Years to 16 Years |
| Sex | All |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Trial ID | NCT04821908 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess how the COVID-19 pandemic has affected asthma control in children aged 3-16 years. It will compare current data on asthma exacerbations and control with historical data from prior to the pandemic. The study will involve clinical assessments and the collection of biological and microbiological samples from a sub-population of children experiencing exacerbations. The findings will help understand the indirect effects of the pandemic on pediatric asthma management.
Who should consider this trial
Good fit: Ideal candidates are children aged 3-16 years with a medical diagnosis of asthma who have been followed for at least 6 months.
Not a fit: Patients with chronic respiratory diseases other than asthma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights that improve asthma management strategies for children during and after public health crises.
How similar studies have performed: While the specific impact of the COVID-19 pandemic on childhood asthma is novel, similar observational studies have successfully assessed the effects of environmental factors on asthma control.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children and adolescents aged 3 to 16 years old * With a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months, * Assessed in one of the pediatric departments participating in the study, * After written consent of at least one of the 2 parents and/or representative of the parental authority, and of the child if he is older than 8 years old. Criteria for the sub-population assessed at "exacerbation" and second visit: * Children and adolescents aged 3 to 16 years * With a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months, * Hospitalized for a severe asthma exacerbation (requiring hospitalization and general corticosteroid therapy) at Lille University Hospital * After written consent of both parents and/or representative of the parental authority, and of the child if he is over 8 years old Exclusion Criteria: * History of chronic respiratory disease other than asthma, * Inability of parents to receive informed information, inability to participate in the entire study, refusal to sign the consent form
Where this trial is running
Lille
- CHU Lille — Lille, France (Recruiting)
Study contacts
- Principal investigator: Stéphanie Lejeune, MD — University Hospital, Lille
- Study coordinator: Stéphanie Lejeune, MD
- Email: stephanie.lejeune@chru-lille.fr
- Phone: 0320445962
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.